Why 2026 Will Be a Big Year for Cannabis M&A

The cannabis industry is about to experience the biggest M&A wave in its history. Are you ready?

If you’re running a cannabis business right now, you’re sitting on the edge of what could be the most transformative year in our industry’s short legal history. 2026 isn’t just another year: it’s the year everything changes.

What you’ll find in this analysis:

• Why Schedule III rescheduling creates a perfect storm for M&A activity
• How 280E relief changes the cash position of buyers and sellers
• What rescheduling does and doesn’t change for deal financing
• What cannabis-specific diligence has to cover
• Specific steps to position your business for maximum opportunity

Here’s the thing that most people in our industry don’t fully grasp yet: for medical operators this is more than a tax break. Better cash flow and cleaner financials change what buyers and sellers can do, and if adult-use follows, the effect widens.

The Schedule III Game Changer Everyone’s Talking About

Let’s start with the obvious: cannabis has started moving from Schedule I to Schedule III. State-licensed medical cannabis made that move on April 28, 2026; adult-use cannabis is still in Schedule I while the DEA’s administrative hearing continues. Track the status on our Cannabis Rescheduling Tracker. But if you think this is just about being able to deduct normal business expenses, you’re missing the bigger picture.

Here’s what 280E relief really means for your bottom line:

For years, cannabis businesses have been hemorrhaging cash to the IRS. Section 280E has forced operators to pay federal taxes on gross profit instead of net profit. I’ve seen 280E push a business’s federal tax bill far above what a comparable business outside cannabis would pay. That’s not a tax: that’s a wealth extraction machine.

When 280E relief reaches a business, that money doesn’t just disappear. It flows straight back into the business as working capital. And here’s where it gets interesting: businesses with suddenly improved cash flow and financial health become much more attractive acquisition targets and much more capable acquirers.

Think about it this way: if 280E is pushing your effective tax rate far above 21%, a move to the normal 21% corporate rate on true net profit is the kind of financial transformation that triggers M&A activity. That drop is closest to real for medical-only operators, pending IRS guidance on whether relief requires DEA registration. For operators with both medical and adult-use licenses, the medical side is unresolved, because the DEA has not registered any of them. For adult-use cannabis it is not final: adult-use remains in Schedule I and 280E still applies until that changes.

Why Capital Will Finally Flow in 2026

But here’s where most analysis stops, and where we need to dig deeper. The banking situation is about to change dramatically, and this might be even more important than the tax relief.

Right now, cannabis M&A deals are incredibly complicated because of banking restrictions. Try explaining to a traditional lender why you need financing for a cannabis acquisition. Try getting a line of credit for expansion. Try setting up normal escrow services for a deal.

Banking access improvements will solve three critical M&A barriers:

• Deal financing becomes possible: Traditional debt financing for acquisitions has been nearly impossible. Banks couldn’t touch cannabis deals without risking federal compliance issues.
• Due diligence gets professional: When banks can officially work with cannabis businesses, the entire professional services ecosystem opens up. Think institutional-grade financial auditing, standardized valuation models, and proper deal documentation.
• Institutional capital enters the market: This is the big one. Pension funds, insurance companies, and other institutional investors have been locked out because of banking restrictions. Schedule III begins to change that equation.

I’ve been watching this industry for over a decade, and I can tell you that access to institutional capital is what separates real industries from speculative markets. When institutional money flows in, M&A activity explodes because suddenly you have buyers with real balance sheets and sellers with proper valuations.

The Perfect Storm: Why 2026 Specifically

You might be wondering: why 2026 and not 2025 or 2027? Here’s why the timing creates a perfect storm:

2025 was the preparation year. Smart operators spent 2025 cleaning up their books, getting compliant, and positioning themselves for rescheduling. The businesses that did this work are going to be the winners in 2026.

2026 is implementation year. This is when the regulatory changes actually hit balance sheets. When 280E relief flows through quarterly reports. When banking relationships get established. When institutional investors start making calls.

2027 and beyond is competition year. By then, everyone will understand the new landscape. The easy deals will be done. Competition will be fierce.

If you’re thinking about M&A, whether buying, selling, or merging, 2026 is the year to get your books and structure ready.

What Generic M&A Advice Misses in Cannabis

Cannabis deals run under rules that standard M&A playbooks weren’t built for. Generic frameworks often miss that:

• Compliance has to be checked state by state, license by license
• Due diligence has to cover 280E history, cost of goods calculations and the medical/adult-use split
• Deal structures have to fit state licensing, change-of-ownership approvals and regulatory timelines

That is the work we focus on.

How Buds Group Approaches Cannabis M&A

Here’s our approach to cannabis M&A:

• Valuation that actually makes sense: We don’t just run DCF models and call it done. We understand how licensing values work, how regulatory changes affect multiples, and how to price the optionality that comes with cannabis assets.
• Deal structuring for cannabis reality: Standard M&A structures don’t work when you’re dealing with state licensing requirements, regulatory compliance transfers, and federal tax uncertainty. We structure deals around those realities so they can close.
• Due diligence that catches cannabis-specific risks: Financial due diligence in cannabis means understanding cost of goods calculations under 280E, compliance audit trails, licensing contingencies, and regulatory risk assessment.
• Implementation that works in our regulatory environment: Closing the deal is just the beginning. We help with license transfers, regulatory notifications, compliance integration, and post-merger operational alignment.

Real Talk: What This Means for Your Business

Let me give you some specific scenarios to think about:

If you’re a smaller operator: 2026 might be your best exit opportunity. Larger MSOs are going to have capital to spend and pressure to grow. Your business might be worth significantly more in 2026 than it was in 2024.

If you’re a mid-size operator: This is make-or-break time. You either use 2026 to acquire smaller players and compete with the big guys, or you get acquired. Standing still isn’t an option.

If you’re an MSO: You have the resources to be aggressive, but you also have the most to lose if you make the wrong moves. Strategic acquisitions in 2026 could set you up for the next decade, but overpaying could cripple your growth.

The Strategic Planning You Need to Start Today

Here’s what you should be doing right now if you want to maximize your M&A opportunities in 2026:

• Financial house cleaning: Get your books audit-ready. Understand what your financials look like with and without 280E relief, channel by channel. Build pro forma models that show your true earning potential.
• Regulatory compliance review: Make sure all your licenses are clean, all your compliance documentation is current, and all your regulatory relationships are solid.
• Strategic positioning: Identify potential acquisition targets or potential acquirers. Start building relationships now, before everyone else figures out the opportunity.
• Capital planning: Understand your financing options under the new banking rules. Build relationships with lenders who are preparing for cannabis. Get your debt capacity analyzed.

Why Timing Matters More Than You Think

I’ve been part of enough M&A cycles to know that timing isn’t everything: it’s the only thing. The difference between selling your business in Q1 2026 versus Q4 2026 could be millions of dollars.

Early movers in M&A cycles get the best valuations. Late movers get what’s left. And if you’re not moving at all, you’re getting moved by someone who is.

The window is opening, but it won’t stay open forever.

Smart money is already positioning for 2026. Private equity firms are raising cannabis-focused funds. Strategic acquirers are building war chests. Investment bankers are studying the space.

If you’re running a cannabis business and you’re not thinking about M&A strategy for 2026, you’re already behind.

Related Reading

• Current status, medical and adult-use: Cannabis Rescheduling Tracker
• What the medical/adult-use split means for your books: The Bifurcation Is Official: 280E Relief for Medical Cannabis
• The executive order that started the clock: Executive Order Signed: Cannabis Moving from Schedule I to Schedule III
• Step-by-step accounting prep: How to Prepare Your Cannabis Accounting for Schedule III Rescheduling

Ready to Make Your Move?

The cannabis industry has never seen an opportunity like what’s coming in 2026. Federal rescheduling, 280E relief, banking access, and institutional capital are creating the perfect conditions for M&A activity.

But opportunity without execution is just wishful thinking.

At Buds Group, we help cannabis businesses navigate these transitions. Whether you’re looking to buy, sell, or position strategically, our M&A advisors can help you understand your options and execute your strategy.

The question isn’t whether M&A activity will surge in 2026: it’s whether you’ll be ready to capitalize on it.

Want to explore your M&A options? Let’s talk. Contact Buds Group to discuss how we can help position your business in the biggest M&A year cannabis has ever seen.